Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Qian, L., Zheng, J., Wang, K., Tang, Y., Zhang, X., Zhang, H., et al. (2013). Cationic core-shell nanoparticles with carmustine contained within O6 benzylguanine shell for glioma therapy. Biomate, 34(35), 8968–8978.
2. Dhakane, V. D., & Ubale, M. B. (2012). A validated stability-indicating HPLC related substances method for carmustine in bulk drug. Elixir International Journal Pharmaceuticals, 50, 10383–10386.
3. Grassin-Delyle, S., Buenestado, A., Naline, E., Faisy, C., Blouquit-Laye, S., Couderc, L. J., et al. (2012). Intranasal drug delivery: An efficient and non-invasive route for systemic administration focus on opioids. Pharmacology & Therapeutics, 134(3), 366–379.
4. Preusser, M., Ribaupierre, S. D., & Wöhrer, A. (2011). Current concepts and management of glioblastoma. Annals of Neurology, 70, 9–21.
5. Johnson, K. J. C., Cullen, J., & Barnholtz Sloan, J. S. (2014). Childhood brain tumor epidemiology: A brain tumor epidemiology consortium review. Cancer Epidemiology, Biomarkers & Prevention, 23, 2716–2736.